News from Wednesday, January 29, 2025
Articles
Real-World Study Suggests Fewer ALS Progression Milestones With Edaravone
(1/29, Jaymin Kang, PharmD, Medical Professionals Reference) reports “Treatment with intravenous (IV) edaravone was associated with fewer reported disease progression milestones and deaths in patients with amyotrophic lateral sclerosis (ALS), according to real-world data published in the Journal of Comparative Effectiveness Research...The retrospective, observational, comparative effectiveness cohort study utilized health claims data from the Optum Clinformatic® Data Mart, a database composed of both commercial and Medicare Advantage plan members.” Full
Belgian Agency To Lead EU Joint Clinical Assessments Under HTA Regulation
(1/29, Francesca Bruce, Pink Sheet) reports “...The Belgian health technology assessment (HTA) body, INAMI-RIZIV, will lead the consortium of EU member state HTA bodies that will carry out joint clinical assessments (JCA) under the HTA Regulation. In this role, the Belgian body will draw on its experience gained through the BeNeLuxA cross-country coalition, which among other things conducts joint HTAs for new medicines.” Subscription Required
Press Releases
Addressing Challenges on Patients’ Path to Cell and Gene Therapy Treatment Is Crucial to Improving Access and Outcomes
(1/29, National Pharmaceutical Council Press Release) “A new white paper from the National Pharmaceutical Council (NPC) analyzes the challenges faced by patients and caregivers pursuing cell and gene therapy and offers recommendations to improve patient outcomes and access to these life-changing treatments. The publication, ‘Cell and Gene Therapy: Patient and Caregiver Odyssey,’ was authored by Tyler D. Wagner, PharmD, PhD; Brian Sils, MPP; and Jonathan D. Campbell, PhD, MS.” Full
Journals
Longer Disease Progression Milestone-free Time in People with Amyotrophic Lateral Sclerosis Treated Versus Not Treated with Intravenous Edaravone: Results from an Administrative Claims Analysis
James D Berry, et al.
January 21, 2025, Journal of Comparative Effectiveness Research
Journal of Comparative Effectiveness Research
The Comparative Effectiveness of Medicinal Cannabis for Chronic Pain Versus Prescription Medication Treatment
Ajay D Wasan, et al.
January 24, 2025, Pain
Comparison of B-Cell Depletion Versus Natalizumab for Treatment of Multiple Sclerosis: A Semi-Supervised Causal Analysis
Dominic DiSanto, et al.
January 27, 2025, medRxiv
Interleukin-23 versus Interleukin-17 Inhibitors in Preventing Incidental Psoriatic Arthritis in Patients with Psoriasis: A Real-World Comparison From the TriNetX US Collaborative Network
Sebastian Yu, et al.
January 29, 2025, BioDrugs
Propensity Score Matching: Should We Use it in Designing Observational Studies?
Fei Wan
January 29, 2025, BMC Medical Research Methodology